Literature DB >> 498160

cis-Dichlorodiamminepltinum(II) in adult patients: Southwest Oncology Group Studies.

R Stephens, C Coltman, A Rossof, M Samson, F Panettiere, M Al-Sarraf, D Alberts, J Bonnet.   

Abstract

In addition to cis-dichlorodiammineplatinum(II) studies in lymphomas and testicular cancer and a broader phase II study of all genitourinary malignancies, the Southwest Oncology Group is currently conducting eight other studies which examine the effectiveness of this drug in adult patients with a variety of tumor types. This report will give preliminary analyses of the five studies for which there are early data, plus briefly describe the design of the three remaining protocols for which there are no data as yet.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498160

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

Review 1.  Head and neck cancer: guidelines for chemotherapy.

Authors:  G Catimel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 2.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

3.  High-dose cisplatin in advanced head and neck cancer.

Authors:  A A Forastiere; B J Takasugi; S R Baker; G T Wolf; V Kudla-Hatch
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain.

Authors:  D J Stewart; L G Feun; M Maor; M Leavens; M A Burgess; R S Benjamin; G P Bodey
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.